Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencing

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Markman M. Advances in cervical cancer pharmacotherapies. Exp Rev Clin Pharmacol. 2014;7:219–223.
   PubMed Web of Science ®Google Scholar
• Cadron I, Van Gorp T, Amant F, et al. Chemotherapy for recurrent cervical cancer. Gynecol Oncol. 2007;107:S1138.
   Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene. 2003;22:8983–8998.
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–189.
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11:32–50.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489.
   PubMed Web of Science ®Google Scholar
• Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23:1515–1527.
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Zuco V, Gatti L, et al. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem. 2013;20:1923–1945.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Navolanic P, Chappell WH, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011;10:3003–3015.
   PubMed Web of Science ®Google Scholar
• Stahl JM. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002–7010.
   PubMed Web of Science ®Google Scholar
• Joy A, Kapoor M, Georges J, et al. The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. J Neurooncol. 2016;130:43–52.
   PubMed Web of Science ®Google Scholar
• Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44:941–945.
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99:1265–1268.
   PubMed Web of Science ®Google Scholar
• Wei W. miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis. 2013;4:e668–e668.
   PubMed Web of Science ®Google Scholar
• Shao Y. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010;70:6670–6681.
   PubMed Web of Science ®Google Scholar
• Gagnon V, Mathieu I, Sexton E, et al. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004;94:785–795.
   PubMed Web of Science ®Google Scholar
• Gagnon V, Themsche C, Turner S, et al. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008;13:259.
   PubMed Web of Science ®Google Scholar
• Grottke A, Ewald F, Lange T, et al. Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. PloS One. 2016;11:e0146370.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim YY, Jee HJ, et al. Akt3 knockdown induces mitochondrial dysfunction in human cancer cells. Acta Biochim Biophys Sin (Shanghai). 2016;48:447–453.
   PubMed Web of Science ®Google Scholar
• Yadav SS, Li J, Lavery HJ, et al. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urol Oncol. 2015;33:267.e1–13.
   PubMed Web of Science ®Google Scholar
• Lin W, Feng M, Li X, et al. Transcriptome profiling of cancer and normal tissues from cervical squamous cancer patients by deep sequencing. Mol Med Rep. 2017;16:2075–2088.
   PubMed Web of Science ®Google Scholar
• Mutz KO, Heilkenbrinker A, Lonne M, et al. Transcriptome analysis using next-generation sequencing. Current Opinion in Biotechnology. 2013;24:22–30.
   PubMed Web of Science ®Google Scholar
• Kim D, Pertea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
   PubMed Web of Science ®Google Scholar
• Langmead B, Trapnell C, Pop M, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.
   PubMed Web of Science ®Google Scholar
• Wadhwa B, Makhdoomi U, Vishwakarma R, et al. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. Anticancer Drugs. 2017;28:569–580.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–1883.
   PubMed Web of Science ®Google Scholar
• Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706–721.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004.
   PubMed Web of Science ®Google Scholar
• Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005;10:975–987.
   PubMed Web of Science ®Google Scholar
• Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–3997.
   PubMed Web of Science ®Google Scholar
• Grabinski N, Mollmann K, Milde-Langosch K, et al. AKT3 regulates ErbB2, ErbB3 and estrogen receptor alpha expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Cell Signal. 2014;26:1021–1029.
   PubMed Web of Science ®Google Scholar
• Wu H, Xiao Z, Zhang H, et al. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs. 2014;25:799–809.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yoshioka Y, Minoura K, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011;10:135.
   PubMed Web of Science ®Google Scholar